Wikipedia -WSS

Wikipedia

author：explore 2025-08-24 05:25:47 - browse：93553

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Disclosing genetic information: not as worrisome as once feared

hotspot

WSS

Rise in cancer among younger people worries and puzzles doctors

In the gardens at Boston Children's Hospital, families find sanctuary

What to watch for from Zogenix and Amicus clinical trials

Paxlovid study fails to answer questions over benefit for broader groups

Why we need to separate burnout from moral injury in health care

The battle over 'scope creep' and who gets to be called 'doctor'

focus

Wikipedia

leisure time

Cancer drug shortages should be causing more outrage

New Alzheimer's drugs heat up race for early detection blood tests

BioMarin wins approval for gene therapy to treat hemophilia A

Death of patient in Alzheimer’s trial raises question of possible risks

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Former reverend arrested for allegedly killing 8

How to save PrEP access — and even expand it

Disclosing genetic information: not as worrisome as once feared

How one medical school became remarkably diverse

What to watch for from Zogenix and Amicus clinical trials

hotspot

UHS says company favors patients whose insurance pays more

How doctors’ personal politics affect patients

What causes rare myocarditis in young men after Covid vaccines?

The battle over the Brookhaven Landfill on Long Island

Paxlovid study fails to answer questions over benefit for broader groups

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

focus

hotspot

hotspot